Saama
Saama, a life sciences AI company, has faced recent operational challenges as its primary website and key subdomains have been offline since at least mid-2025, displaying only WP Engine hosting error messages.
Profile
Provides AI-powered clinical data analytics for life sciences companies.
Saama, a life sciences AI company, has faced recent operational challenges as its primary website and key subdomains have been offline since at least mid-2025, displaying only WP Engine hosting error messages. The company's founder and CEO Suresh Katta was nominated in April 2024 to join Novavax's board by activist investor Shah Capital, suggesting some continued industry relevance. Prior to its web presence issues, Saama positioned itself as an AI clinical analytics provider for pharmaceutical and healthcare organizations, with a focus on revenue cycle management and digital care coordination solutions.
The company's 2025 AI Breakthrough Award claim for 'Best AI-Based Life Sciences Solution' cannot be independently verified due to the website outage. Saama's current financial health and headcount are unclear, with no recent funding announcements or SEC filings available post-2024.
Who buys this
- Pharmaceutical companies conducting clinical trials
- Healthcare providers managing patient data
- Biotech firms needing regulatory compliance support
- Medical research organizations
Strengths and what to watch
Strengths
- CEO has biotech industry recognition as evidenced by Novavax board nomination
- Prior focus on specialized life sciences AI applications
- Claimed 2025 industry award (unverifiable due to website issues)
Watch for
- Extended website outage suggests possible operational or financial distress
- No verifiable customer case studies or recent client announcements
- Dependence on CEO's reputation without clear product visibility
Key Information
- Founded
- 1997
- Headquarters
- Campbell, CA
Frequently Asked Questions
What does Saama do?
Saama provides AI-powered clinical data analytics for life sciences companies, focusing on pharmaceutical and healthcare organizations. Their solutions include revenue cycle management and digital care coordination, aimed at improving clinical trial efficiency and patient data management.
Who are Saama's primary customers?
Saama primarily serves pharmaceutical companies conducting clinical trials, healthcare providers managing patient data, biotech firms needing regulatory compliance support, and medical research organizations. Their solutions are tailored to meet the specific needs of these sectors.
What is the status of Saama's website?
Saama's primary website and key subdomains have been offline since at least mid-2025, displaying WP Engine hosting error messages. This extended outage raises concerns about the company's operational and financial health, as no recent updates or client announcements are available.
Has Saama won any industry awards?
Saama claimed to have won the 2025 AI Breakthrough Award for 'Best AI-Based Life Sciences Solution.' However, this claim cannot be independently verified due to the ongoing website outage and the unavailability of the award announcement page.
What is known about Saama's CEO, Suresh Katta?
Suresh Katta, Saama's founder and CEO, was nominated in April 2024 to join Novavax's board by activist investor Shah Capital. This nomination highlights his continued industry relevance and recognition within the biotech sector.
What are the concerns about Saama's current operations?
Concerns about Saama include its extended website outage, lack of verifiable customer case studies, and dependence on CEO Suresh Katta's reputation without clear product visibility. These issues suggest possible operational or financial distress within the company.
Sources
- www.reuters.com — CEO Suresh Katta's nomination to Novavax board
- www.saama.com — Website outage evidence
- www.saama.com — Unverifiable award claim due to 404 error
- www.saama.com — Investor relations page unavailable